A phase 3 pivotal clinical study of Haduvio in chronic cough in IPF
Latest Information Update: 07 Mar 2025
At a glance
- Drugs Nalbuphine (Primary)
- Indications Cough
- Focus Registrational; Therapeutic Use
- Sponsors Trevi Therapeutics
Most Recent Events
- 25 Feb 2025 According to a Trevi Therapeutics media release, the results from CORAL study will help us determine the optimal doses of Haduvio to move into pivotal Phase 3 program.
- 18 Aug 2022 New trial record
- 11 Aug 2022 According to a Trevi Therapeutics media release, the company is actively preparing for this trial in chronic cough in IPF and are looking forward to discussing the program and trial plan with the FDA at a meeting scheduled for this quarter.